Impact of depression on health utility value in cancer patients

被引:18
作者
Fujisawa, Daisuke [1 ,2 ,3 ]
Inoguchi, Hironobu [3 ]
Shimoda, Haruki [4 ,5 ]
Yoshiuchi, Kazuhiro [6 ]
Inoue, Shinichiro [7 ]
Ogawa, Asao [3 ]
Okuyama, Toru [8 ]
Akechi, Tatsuo [8 ]
Mimura, Masaru [1 ,2 ]
Shimizu, Ken [3 ]
Uchitomi, Yosuke [9 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo 108, Japan
[2] Keio Univ, Sch Med, Palliat Care Ctr, Tokyo 108, Japan
[3] Natl Canc Ctr, Dept Psychooncol, Tokyo, Japan
[4] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Dept Mental Hlth Policy & Evaluat, Tokyo, Japan
[5] Univ Tokyo, Dept Mental Hlth, Tokyo 1138654, Japan
[6] Univ Tokyo, Dept Stress Sci & Psychosomat Med, Tokyo 1138654, Japan
[7] Okayama Univ, Dept Neuropsychiat, Okayama 7008530, Japan
[8] Nagoya City Univ, Dept Psychiat & Cognit Behav Med, Nagoya, Aichi, Japan
[9] Natl Canc Ctr, Innovat Ctr Support Palliat & Psychosocial Care, Tokyo, Japan
关键词
cancer; oncology; QALY; DALY; EQ-5D; depression; QUALITY-OF-LIFE; BREAST-CANCER; JAPANESE VERSION; EQ-5D; SYMPTOM; SCORES; RADIOTHERAPY; OUTPATIENTS; VALIDATION; PREDICTORS;
D O I
10.1002/pon.3945
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe quality-adjusted life year, which is usually calculated from the health utility value, is now a standard measurement used in political decision-making in health. Although depression is the leading cause of decrement in health utility in general population, impact of comorbid depression among cancer patients has not been studied sufficiently. Therefore, this study aimed to measure the impact of depression on cancer patients' health utility score, according to the severity of depression. MethodsImpact of depression severity (measured by the Patient Health Questionnaire) on health utility score (measured by the EuroQoL-5 scale) was evaluated in a sample of 328 Japanese cancer patients, controlling for performance status, symptom burden, and demographic variables. ResultsThe patients with depression had significantly lower health utility value than those without depression (mean decrement=0.14). Decrements in health utility of 0.13, 0.18, and 0.19 were observed for mild, moderate, and moderately severe to severe level of depression, respectively. The difference was significant between groups. Depression severity was a significant predictor for health utility (standardized coefficient beta=-0.25), which was comparable with physical symptom burden and performance status. Participants' age, gender, cancer stage, and comorbid illness were not significant. The model explained 37.9% of the variance. ConclusionsEven mild level of depression caused clinically meaningful decrement in health utility value in cancer patients, which was comparable with decrements due to major physical complications of cancer. Influence of depression should be carefully investigated when interpreting the quality-adjusted life year among cancer patients. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:491 / 495
页数:5
相关论文
共 39 条
[21]  
Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
[22]   The patient health questionnaire, Japanese version: Validity according to the mini-international neuropsychiatric interview-plus [J].
Muramatsu, Kumiko ;
Miyaoka, Hitoshi ;
Kamijima, Kunitoshi ;
Muramatsu, Yoshiyuki ;
Yoshida, Masahito ;
Otsubo, Tempei ;
Gejyo, Fumitake .
PSYCHOLOGICAL REPORTS, 2007, 101 (03) :952-960
[23]  
National Institute for Health and Clinical Excellence, 2013, GUID METH TECHN APPR
[24]   Japanese version of the MD Anderson symptom inventory: A validation study [J].
Okuyama, T ;
Wang, XS ;
Akechi, T ;
Mendoza, TR ;
Hosaka, T ;
Cleeland, CS ;
Uchitomi, Y .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 26 (06) :1093-1104
[25]   Comorbidity is an independent predictor of health-related quality of life in a longitudinal cohort of head and neck cancer patients [J].
Osthus, Arild Andre ;
Aarstad, Anne K. H. ;
Olofsson, Jan ;
Aarstad, Hans J. .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (05) :1721-1728
[26]   What symptom and functional dimensions can be predictors for global ratings of overall quality of life in lung cancer patients? [J].
Ostlund, Ulrika ;
Wennman-Larsen, Agneta ;
Gustavsson, Petter ;
Wengstrom, Yvonne .
SUPPORTIVE CARE IN CANCER, 2007, 15 (10) :1199-1205
[27]   Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance [J].
Parker, Patricia A. ;
Davis, John W. ;
Latini, David M. ;
Baum, George ;
Wang, Xuemei ;
Ward, John F. ;
Kuban, Deborah ;
Frank, Steven J. ;
Lee, Andrew K. ;
Logothetis, Christopher J. ;
Kim, Jeri .
BJU INTERNATIONAL, 2016, 117 (03) :469-477
[28]   Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer [J].
Pickard, A. Simon ;
Neary, Maureen P. ;
Cella, David .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2007, 5 (1)
[29]   Health utilities using the EQ-5D in studies of cancer [J].
Pickard, A. Simon ;
Wilke, Caitlyn T. ;
Lin, Hsiang-Wen ;
Lloyd, Andrew .
PHARMACOECONOMICS, 2007, 25 (05) :365-384
[30]   EQ-5D: a measure of health status from the EuroQol Group [J].
Rabin, R ;
de Charro, F .
ANNALS OF MEDICINE, 2001, 33 (05) :337-343